好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Frequency, Classification, and Timing of Movement Disorders in Rapidly Progressive Dementia
Movement Disorders
P14 - Poster Session 14 (11:45 AM-12:45 PM)
5-004
To compare and classify movement disorders in patients with specific causes of rapidly progressive dementia (RPD).
Many diseases present with RPD. The broad differential presents a unique challenge for the clinician who must rapidly organize and interpret tests to provide a timely clinical diagnosis for the patient with RPD. Movement disorders are associated with several different causes of RPD; their emergence, classification, and progression may provide clues to the specific diagnosis in patients with RPD.
Patients with RPD were prospectively enrolled between February 2016 and August 2022 at two tertiary care centers. Two neurologists independently determined etiologic diagnoses. A third neurologist systematically reviewed research records to identify movement disorders (e.g., parkinsonism, tremor, ataxia, myoclonus, dystonia, etc.) and classified these when present. Associations between movement disorders and specific causes of RPD were considered using Fisher’s exact test.
154 patients met criteria for RPD (46.7% female). The median age-at-symptom onset was 66.0 years old (range: 18.3-84.7 years). Movement disorders were detected at presentation in 45/154 (29.2%) patients and in 73/154 (47.4%) patients at some point in the illness course. Gait disorders (n=40, 52.6%) were the most frequent movement disorder observed, followed by tremor (n=30, 40.5%), rigidity (n=24, 32.4%), ataxia (n=19, 25.7%) and myoclonus (n=19, 25.7%). Movement disorders were more commonly associated with prion disease (OR=3.65, 95% CI 1.27-11.93, p=0.008), and appeared on average 89 days after symptomatic onset. Detection of myoclonus (OR=6.80, 95%CI 2.0-22.54, p<0.005) was associated with higher odds of CJD, with average time from symptom onset to myoclonus of 118 days. Bradykinesia was associated with Alzheimer disease related dementias (OR=7.38, 95%CI 1.54-46.14, p=0.004).
Detection and classification of movement disorders may inform etiologic diagnosis in patients with RPD.
Authors/Disclosures
Pierpaolo Turcano, MD (Rush University Medical Center)
PRESENTER 		Dr. Turcano has nothing to disclose.
Nihal Satyadev, MD, MPH (Mayo Clinic) Dr. Satyadev has nothing to disclose.
Philip W. Tipton, MD Dr. Tipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Tipton has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Alzheimer's Tennessee. Dr. Tipton has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Charlotte County Medical Society, Inc.
Gregory S. Day, MD, MSc, FAAN (Mayo Clinic) Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys Therapeutics. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for DynaMed (EBSCO Health). Dr. Day has or had stock in ANI Pharmaceuticals. The institution of Dr. Day has received research support from National Institutes of Health / NIA. The institution of Dr. Day has received research support from National Institutes of Health / NINDS. The institution of Dr. Day has received research support from Amgen Pharmaceuticals. The institution of Dr. Day has received research support from AVID Radiopharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at Annual Meeting (CME) with 好色先生. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development (CME) with PeerView, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Continuing 好色先生, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Ionis Pharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a 好色先生al Case Development + Presentation (video) with PeerDirect (P\S\L Group). Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development / Presentation (non-CME) with MJH Life Sciences (NeurologyLive). Dr. Day has a non-compensated relationship as a Clinical Director with Anti-NMDA Receptor Encephalitis Foundation that is relevant to AAN interests or activities.